1363. Preliminary Safety Results from a Phase 1 First in Human Study of VYD222: an Extended Half-Life Monoclonal Antibody (mAb) in Development for COVID-19 Prevention

ABSTRACT:

SUBMITTER:  

PROVIDER: S-EPMC10678193 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature